Samsung BioLogics losses not as bad in Q3 this year
Samsung BioLogics, a biopharmaceutical unit of Samsung, said Tuesday its third-quarter net losses narrowed slightly from a year earlier on reduced equity deficit from its affiliates.For the three month period ending Sept. 30, net losses shrank to 30.14 billion won ($26.5 million) from 31.69 billion won a year earlier, the company said in a regulatory filing.
Operating profit fell 49 percent to 10.4 billion won in the third quarter from 20.4 billion won a year ago. Sales fell 21 percent to 101 billion won from 127.4 billion won.
Yonhap
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)